Long-chain fatty acids (FA) coordinately induce the expression of a panel of genes involved in cellular FA metabolism in cardiac muscle cells, thereby promoting their own metabolism. These effects are likely to be mediated by peroxisome proliferator-activated receptors (PPARs). Whereas the significance of PPARalpha in FA-mediated expression has been demonstrated, the role of the PPARbeta/delta and PPARgamma isoforms in cardiac lipid metabolism is unknown. To explore the involvement of each of the PPAR isoforms, neonatal rat cardiomyocytes were exposed to FA or to ligands specific for either PPARalpha (Wy-14,643), PPARbeta/delta (L-165041, GW501516), or PPARgamma (ciglitazone and rosiglitazone). Their effect on FA oxidation rate, expression of metabolic genes, and muscle-type carnitine palmitoyltransferase-1 (MCPT-1) promoter activity was determined. Consistent with the PPAR isoform expression pattern, the FA oxidation rate increased in cardiomyocytes exposed to PPARalpha and PPARbeta/delta ligands, but not to PPARgamma ligands. Likewise, the FA-mediated expression of FA-handling proteins was mimicked by PPARalpha and PPARbeta/delta, but not by PPARgamma ligands. As expected, in embryonic rat heart-derived H9c2 cells, which only express PPARbeta/delta, the FA-induced expression of genes was mimicked by the PPARbeta/delta ligand only, indicating that FA also act as ligands for the PPARbeta/delta isoform. In cardiomyocytes, MCPT-1 promoter activity was unresponsive to PPARgamma ligands. However, addition of PPARalpha and PPARbeta/delta ligands dose-dependently induced promoter activity. Collectively, the present findings demonstrate that, next to PPARalpha, PPARbeta/delta, but not PPARgamma, plays a prominent role in the regulation of cardiac lipid metabolism, thereby warranting further research into the role of PPARbeta/delta in cardiac disease.

Download full-text PDF

Source
http://dx.doi.org/10.1161/01.RES.0000060700.55247.7CDOI Listing

Publication Analysis

Top Keywords

pparbeta/delta ppargamma
16
pparalpha pparbeta/delta
16
cardiac lipid
12
lipid metabolism
12
promoter activity
12
ppargamma ligands
12
pparbeta/delta
11
peroxisome proliferator-activated
8
expression genes
8
genes involved
8

Similar Publications

How PPAR-alpha mediated inflammation may affect the pathophysiology of chronic kidney disease.

Curr Res Physiol

November 2024

Department of Physiology and Biophysics, College of Medicine, Howard University, Washington, DC, USA.

Article Synopsis
  • Chronic kidney disease (CKD) significantly increases the risk of death in adults, and inflammation is a key factor in its development, although the exact mechanisms are not well understood.
  • The peroxisome proliferator-activated receptor alpha (PPAR-α) is a crucial nuclear receptor that can help reduce the harmful effects associated with CKD, but its specific role, especially regarding inflammation, remains unclear compared to other PPAR members.
  • This review focuses on understanding the function of PPAR-α in CKD and its potential implications for the immune system's involvement in the disease.
View Article and Find Full Text PDF

Introduction: Prostate cancer is a major public health challenge for men worldwide, being the second most common cancer diagnosis and the fifth leading cause of cancer-related deaths among men. The etiology of prostate cancer is multifactorial, with age, genetic predispositions, and lifestyle factors playing critical roles. The role of the peroxisome proliferator-activated receptors (PPARs) in prostate cancer remains complex and not fully elucidated.

View Article and Find Full Text PDF
Article Synopsis
  • The editorial reviews a study by Koizumi on the effects of PPAR agonists, particularly elafibranor, in protecting against intestinal damage and liver fibrosis in a mouse model of alcoholic liver disease (ALD).
  • The article highlights the significance of PPARs in maintaining intestinal health and lipid balance, key factors impacted by ALD, and emphasizes the urgent need for effective treatments due to the disease's growing global impact.
  • It also explores the potential of various PPAR agonists to mitigate liver disease symptoms and discusses the current research challenges and future directions needed for understanding their therapeutic roles in ALD.
View Article and Find Full Text PDF

Application of PPAR Ligands and Nanoparticle Technology in Metabolic Steatohepatitis Treatment.

Biomedicines

August 2024

Department of Anatomy and Regenerative Biology, Graduate School of Medicine, Osaka Metropolitan University, Osaka 545-8585, Osaka, Japan.

Article Synopsis
  • Metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis (MASH) are serious global health issues, making effective treatment a challenge.
  • Peroxisome proliferator-activated receptors (PPARs) are key proteins that help regulate lipid metabolism and have three main types: PPARα, PPARβ/δ, and PPARγ.
  • New therapies are being explored using nanoparticles (NPs) that specifically target PPARα and PPARγ, enhancing drug delivery systems for treating MASLD/MASH.
View Article and Find Full Text PDF

Hepatocellular carcinoma (HCC) holds a prominent position among global cancer types. Classically, HCC manifests in individuals with a genetic predisposition when they encounter risk elements, particularly in the context of liver cirrhosis. Peroxisome proliferator-activated receptors (PPARs), which are transcription factors activated by fatty acids, belong to the nuclear hormone receptor superfamily and play a pivotal role in the regulation of energy homeostasis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!